Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth
Halozyme reports better-than-expected fourth-quarter 2024 results. The company maintains revenue guidance for 2025.
Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript
Halozyme Therapeutics, Inc. (HALO) Q4 2024 Earnings Call Transcript
Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $0.82 per share a year ago.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
HALO Gears Up to Report Q4 Earnings: Here's What You Should Know
Halozyme's fourth-quarter earnings are likely to have gained from higher royalty payments and revenues from collaboration agreements for its Enhanze technology.
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
